#United States #New York #Faruqi & Faruqi #ImmunityBio #IBRX

ImmunityBio Class Action Reminders for Investors

ImmunityBio, Inc. (NASDAQ: IBRX) is currently facing a securities class action that could have significant implications for its investors. Faruqi & Faruqi, LLP, a respected national securities law firm, is leading the investigation into potential claims against the company and urges affected investors to take notice of the impending deadline for participation in the class action lawsuit.

Important Dates and Legal Context

The reminder from Faruqi & Faruqi is particularly pressing, as May 26, 2026, marks the last day for investors to seek the status of lead plaintiff in this case. Investors who purchased ImmunityBio securities between January 19, 2026, and March 24, 2026, and have suffered losses during this period are encouraged to review their options. The firm’s partner, Josh Wilson, asserts that any investor who is interested should not hesitate to reach out to discuss their rights.

Allegations Against ImmunityBio

The lawsuit arises from serious allegations against both ImmunityBio and its executives, specifically citing violations of federal securities laws. It has been reported that Patrick Soon-Shiong, a key figure in the company, made exaggerated claims regarding the capabilities of Anktiva—a drug developed by ImmunityBio. Furthermore, the suit claims that the accuracy of statements concerning the company's business and operational prospects has been called into question, suggesting a pattern of misinformation that has harmed investors.

On January 23, 2026, ImmunityBio disclosed updated Phase 2 trial results related to a combination immunotherapy treatment for glioblastoma. However, the primary endpoint of median overall survival was reported as not yet reached. Following this announcement, the stock price dropped by 12.13%, marking a significant loss for investors.

Being Informed and Taking Action

For potential class members, the court will appoint a lead plaintiff—someone with a financial interest who is typical of other investors affected by the alleged misconduct. Any class member has the option to file a motion to become the lead plaintiff through their chosen counsel. Importantly, choosing to serve as a lead plaintiff or remaining an absent class member will not impact their entitlement to any recovery resulting from the class action.

Faruqi & Faruqi is actively seeking further information about ImmunityBio's corporate conduct from whistleblowers, former employees, and shareholders. This call for information may further strengthen the case against the company as the legal proceedings continue.

Final Thoughts and Contact Information

Investors are encouraged to remain vigilant and informed about the developments concerning ImmunityBio and its legal challenges. For those who believe they may have been impacted, reaching out to Faruqi & Faruqi could provide clarity and direction in navigating this complex situation. Investors can get additional information by visiting the firm's website or contacting Josh Wilson directly at the provided numbers.

As this case unfolds, it will be crucial for affected investors to stay updated and proactive regarding their legal rights and options. Failure to act by the deadline could mean forfeiting a significant opportunity for justice due to potential losses incurred from the alleged malpractices of ImmunityBio.